Company Overview and News

to your dashboard

Headline News

Struggling Teva Announces Mass Layoffs

10h seekingalpha
The clock has been ticking on Teva (TEVA) ever since Mylan's (MYL) generic Copaxone was approved last month. Copaxone represents over 45% of the company's EBITDA and Teva needs to rapidly grow revenue or cut costs to compensate for the loss. New CEO Kare Schultz chose the latter, announcing layoffs of up to 25% of its local workforce in Israel: (134-0)

Applying My Risk Checklist To General Electric And Mylan

2017-11-20 seekingalpha
Part of my process is to go through a risk checklist.  Stocks that don't pass are put aside.  Debt ratios and 3 models (Piotroski, Altman, Beneish) are used and shown. (20-1)

Biocon shares rise 6% after Bengaluru unit gets US FDA clearance

2017-11-20 livemint
Mumbai: Biocon Ltd’s shares jumped 6% after the company said on Monday that its manufacturing facility in Bengaluru, which had received observations relating to lapses in quality compliance earlier this year, has been cleared by the US Food and Drug Administration (FDA). (5-0)

Why Fitch Sacked Teva

2017-11-20 seekingalpha
Generic Copaxone could cause Copaxone sales to decline by 70% and total EBITDA to fall by 34%. (365-3)

Tracking John Paulson's Paulson & Company Portfolio - Q3 2017 Update

2017-11-18 seekingalpha
Paulson & Company's largest three positions are the SPDR Gold ETF, Shire plc, and Mylan NV. (1155-10)

Theravance Shares Rise on Approval of Glaxo's COPD Therapy

2017-11-17 zacks
Theravance Biopharma, Inc.’s (TBPH - Free Report) shares rose almost 6.5% on Thursday following the approval of GlaxoSmithKline plc’s (GSK - Free Report) chronic obstructive pulmonary disease ("COPD") therapy, Trelegy Ellipta in Europe. Investors cheered the approval as Theravance has an economic interest on the royalties that Glaxo will pay to its partner Innoviva, Inc. (INVA - Free Report) on global sales of Trelegy Ellipta. (36-1)

What We Can Learn From Teva's Q3 Report

2017-11-17 seekingalpha
Teva has to sell some of its businesses to (1) raise cash for debt repayment and (2) comply with FTC and EC regulations. (134-1)

Theravance Biopharma: Undervalued With Catalysts

2017-11-16 seekingalpha
There is significant opportunity for norepinephrine serotonin reuptake inhibitor TD-9855 in patients with nOH considering the drug's differentiated profile and current sales of competitor Northera. (7-0)

Tracking David Einhorn's Portfolio - Q3 2017 Update

2017-11-16 seekingalpha
Greenlight's long/short ratio is at 118% long and 73% short compared to 111% long and 79% short last quarter. (1241-9)

Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin

2017-11-14 zacks
Theravance Biopharma, Inc. (TBPH - Free Report) and partner Mylan (MYL - Free Report) announced that the new drug application for the combined entity’s key pipeline candidate, revefenacin (TD-4208), has been submitted to the FDA for treatment of adults with chronic obstructive pulmonary disease (“COPD”). (74-0)

BRIEF-Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

2017-11-10 reuters
* Mylan NV - ‍announced it is voluntarily delisting company’s ordinary shares from trading on tel aviv stock exchange​ (5-0)

FDA Broadens Generic Drug Competition Efforts, Pressuring Prices - Bloomberg

2017-11-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (134-0)

Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND

2017-11-08 zacks
The third-quarter reporting cycle is drawing to a close. Quarterly results have been strong. Overall, the beat percentage is in line with the recent quarters but growth rates have been particularly impressive. Also, the estimate revision trend for Q4 has been mostly favorable. (135-0)

Teva’s stock and bonds walloped after Fitch downgrade to junk - MarketWatch

2017-11-07 marketwatch
Teva Pharmaceutical Industries’s stock slid 6% and its bonds dropped several points Tuesday, after Fitch Ratings downgraded the credit to junk, following disappointing earnings last week. (134-0)

Your Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA Approvals

2017-11-07 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (414-6)

CUSIP: N59465909